EUVIMEDOpdag EUVIMED
Studienprotokoll

Smartphone-Delivered Cognitive Behavioral Digital Therapeutic for Children and Adolescents With Major Depressive Disorder: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Xue Li iD, Qingjiu Cao iD, Li Sun iD, Ying Qian iD, Minglong Gao iD, Lan Wang iD, Wenting Lu iD, Xianglan Wang iD, Hong Wang iD, Xuejiao Hou iD, Jing Liu iD

JMIR Research Protocols · 2026-11-13 · 15 · e103430

DOI: 10.2196/103430 ↗

At a glance

Studienprotokoll in JMIR Research Protocols, published online on 2026-11-13. Written by Xue Li and 10 co-authors. Institution: Beijing Key Laboratory for Big Data Innovative Application of Child and Adolescent Mental Disorders, NHC Key Laboratory of Mental Health, National Cl…. Major MEDLINE topics: Cognitive Behavioral Therapy, Major Depressive Disorder, Smartphone. 32 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Depression is a leading contributor to morbidity and disability in children and adolescents. Cognitive behavioral therapy (CBT) is a guideline-recommended first-line treatment, but access is constrained by therapist supply, distance, and stigma. Internet-based CBT is a scalable adjunct in adults, yet regulatory-grade evidence in Chinese pediatric samples remains limited.

Objective

This trial will determine whether a smartphone-delivered CBT-based digital therapeutic is superior to a matched health-education placebo in reducing depressive symptoms in Chinese children and adolescents with major depressive disorder (MDD), and characterize its safety.

Methods

This is a prospective, multicenter, double-blind, placebo-controlled superiority trial at 4 tertiary-A hospitals in mainland China. Children and adolescents aged 8-17 years meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders [Fifth Edition]) criteria for current MDD without psychotic features and scoring above 30 on the Children’s Depression Rating Scale-Revised (CDRS-R) at screening will be randomized 1:1 to the investigational digital therapeutic (Model WL-PD) or a visually matched health-education placebo. Both arms receive 8 weeks of structured content on an identical schedule; participants with CDRS-R ≥57 additionally receive open-label fluoxetine under weight-banded dosing. The primary end point is CDRS-R total-score reduction from baseline to week 8. Secondary end points include CDRS-R change at weeks 1 to 6; response and remission rates; Clinical Global Impression scores; the Children’s Depression Inventory; the Conners’ Parent Symptom Questionnaire; and a week-8 device-performance evaluation. Safety end points include adverse-event, serious adverse-event, and device-defect incidence. The planned sample of 214 participants (107 per arm) is powered at 80% to detect a between-arm difference of 4.6 CDRS-R points (assumed control SD 10.7) with a 1-sided α of .025 and 20% inflation for attrition. The primary analysis is an analysis of covariance on the full analysis set adjusting for baseline CDRS-R, severity category, fluoxetine exposure, and site; superiority is declared if the lower bound of the 2-sided 95% CI excludes zero, with a mixed model for repeated measures as a sensitivity analysis.

Results

The trial opened to enrollment in March 2026; recruitment is ongoing, with a planned close in December 2026. The last week-8 visit is expected in the first quarter of 2027, and the primary analysis the following year.

Conclusions

The trial addresses 3 recognized gaps in the pediatric digital therapeutics literature: a rigorous, structurally matched blinded control condition, recruitment beyond a single site, and integration of guideline-concordant pharmacotherapy. Because recruitment is confined to tertiary hospitals and excludes participants with prominent suicidality or comorbidity, findings will apply to supervised use in specialist services rather than unselected community care. Trial Registration Chinese Clinical Trial Registry ChiCTR2600120453; https://tinyurl.com/3xzaajhp International Registered Report Identifier (IRRID) DERR1-10.2196/103430

Subjects

MeSH terms (MEDLINE)

Cognitive Behavioral TherapyMajor Depressive DisorderSmartphoneHumansChildAdolescentDouble-Blind MethodMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicEquivalence Trials as TopicChinaMaleFemale

Author keywords

CDRS-Radolescent depressioncognitive behavioral therapydigital therapeuticsrandomized controlled trialstudy protocol

Authors and institutions

  • Beijing Key Laboratory for Big Data Innovative Application of Child and Adolescent Mental Disorders, NHC Key Laboratory of Mental Health, National Clinical Research Center for Mental Disorders, Peking University Sixth H…
  • The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China.

ORCID profiles: Xue Li, Qingjiu Cao, Li Sun, Ying Qian, Minglong Gao, Lan Wang, Wenting Lu, Xianglan Wang, Hong Wang, Xuejiao Hou, Jing Liu

Cite

APA

Li, X., Cao, Q., Sun, L., Qian, Y., Gao, M., Wang, L., Lu, W., Wang, X., Wang, H., Hou, X., & Liu, J. (2026). Smartphone-Delivered Cognitive Behavioral Digital Therapeutic for Children and Adolescents With Major Depressive Disorder: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. JMIR Research Protocols, 15, e103430. https://doi.org/10.2196/103430

Vancouver

Li X, Cao Q, Sun L, Qian Y, Gao M, Wang L, et al. Smartphone-Delivered Cognitive Behavioral Digital Therapeutic for Children and Adolescents With Major Depressive Disorder: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. JMIR Research Protocols. 2026;15:e103430. doi:10.2196/103430

BibTeX
@article{Li2026,
  author = {Li, Xue and Cao, Qingjiu and Sun, Li and Qian, Ying and Gao, Minglong and Wang, Lan and Lu, Wenting and Wang, Xianglan and Wang, Hong and Hou, Xuejiao and Liu, Jing},
  title = {Smartphone-Delivered Cognitive Behavioral Digital Therapeutic for Children and Adolescents With Major Depressive Disorder: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e103430},
  doi = {10.2196/103430}
}
Start for free →